Neurolief Adds Steve Beller as Chief Commercial Officer
New executive expected to lead market launch of new brain neuromodulation technology.
Neurolief announced that it has officially appointed Steve Beller to serve as its new chief commercial officer. According to a company press release, Beller will be placed in charge of strategic planning, commercial partnerships, and preparations for the market launch of Neurolief's novel brain neuromodulation technology for treatment of major depression. Most recently, he ran North America for Nexstim, a transcranial magnetic stimulation (TMS) company focused on brain diseases.
"I am excited to join Neurolief at such an important time for the company while it's seeking regulatory approvals and getting closer to launching its disruptive technology for treatment of major depression," said Mr. Beller. "I believe my commercial leadership experience will be essential in leveraging the unique opportunities we have to gain substantial market share in the vast mental health market."
Reference: Neurolief Appoints Neurotechnology Business Leader Steve Beller as Chief Commercial Officer. PR Newswire. October 11, 2023. Accessed October 12, 2023. https://www.prnewswire.com/news-releases/neurolief-appoints-neurotechnology-business-leader-steve-beller-as-chief-commercial-officer-301953602.html
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
